Form 4: IRADIMED CEO Sells 5,000 Shares Under 10b5-1 Plan

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, reported the sale of 5,000 shares of common stock on November 24, 2025, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Roger E. Susi, CEO, President, and Chairman of IRADIMED Corp, reported the sale of 5,000 shares of common stock.
• The sales occurred on November 24, 2025, through three separate transactions.
• Shares were sold at weighted average prices of $89.67, $90.31, and $91.01.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025.
• Following these sales, the Phillip Susi 2008 Dynasty Trust beneficially owns 2,307,500 shares.
• Roger E. Susi also indirectly beneficially owns 162,950 shares via the Roger E. Susi Revocable Trust and disclaims beneficial ownership of 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust, except for his pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the sales were pre-planned under a Rule 10b5-1 plan, which reduces the negative signaling typically associated with insider selling. However, any insider sale can still be viewed with some caution by investors.

Negatives

• The CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock, which could be perceived negatively by investors as insider selling, despite being pre-planned.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions and does not provide broader industry context or trends. Insider sales, even pre-planned, are often monitored by the market for potential signals, though a 10b5-1 plan mitigates the immediate signaling effect.

Related Party Transactions

• The reporting person disclaims beneficial ownership of 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust, except to the extent of his pecuniary interest therein. This indicates a relationship with the trust, but the disclaimer limits direct beneficial ownership.

Stakeholder Impact

• Shareholders may view the insider sales with caution, although the pre-planned nature under a 10b5-1 plan suggests it's not based on new, undisclosed negative information. The impact is likely minimal given the pre-planned nature.

Key Dates

Recommendation

The filing reports routine insider sales executed under a pre-arranged Rule 10b5-1 trading plan. This type of transaction is generally not indicative of new material information and is often for personal financial planning. Therefore, it does not provide a strong basis for a change in investment recommendation, suggesting a 'hold' position for existing investors.

Keywords

IRADIMED Corp, IRMD, Roger E. Susi, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Beneficial Ownership, CEO, Director, 10% Owner